$APYX
Apyx Medical Corp Stock $apyx

$apyx Overview Financials Valuation SEC Filings Company Website

2017 Q4 Form 10-Q Financial Statement

#000071913517000064 Filed on November 03, 2017

Income Statement

Concept	2017 Q4	2017 Q3	2016 Q3
Revenue	$3.658M	$2.651M	$10.06M
YoY Change	-61.47%	-73.66%	28.63%
Cost Of Revenue	$960.0K	$738.0K	$5.002M
YoY Change	-79.4%	-85.25%	8.98%
Gross Profit	$2.696M	$1.913M	$5.062M
YoY Change	-44.18%	-62.21%	56.77%
Gross Profit Margin	73.7%	72.16%	50.3%
Selling, General & Admin	$4.050M	$2.012M	$2.141M
YoY Change	-22.12%	-6.03%	-52.0%
% of Gross Profit	150.22%	105.18%	42.3%
Research & Development	$340.0K	$487.0K	$681.0K
YoY Change	-50.0%	-28.49%	17.41%
% of Gross Profit	12.61%	25.46%	13.45%
Depreciation & Amortization	$170.0K	$171.0K	$201.0K
YoY Change	0.0%	-14.93%	-4.29%
% of Gross Profit	6.31%	8.94%	3.97%
Operating Expenses	$4.420M	$4.746M	$5.306M
YoY Change	-24.83%	-10.55%	5.07%
Operating Profit	-$1.724M	-$2.833M	-$245.0K
YoY Change	64.19%	1056.33%	-86.55%
Interest Expense	$90.00K	-$110.0K	-$720.0K
YoY Change	-84.75%	-84.72%	-413.04%
% of Operating Profit
Other Income/Expense, Net	$0.00	-$105.0K	-$720.0K
YoY Change		-85.42%
Pretax Income	-$3.140M	-$2.938M	-$965.0K
YoY Change	582.61%	204.46%	-39.31%
Income Tax	$30.00K	$6.000K	$0.00
% Of Pretax Income
Net Earnings	-$820.0K	-$2.944M	-$965.0K
YoY Change	57.69%	205.08%	-39.31%
Net Earnings / Revenue	-22.42%	-111.05%	-9.59%
Basic Earnings Per Share	-$90.00	-$90.00	-$0.04
Diluted Earnings Per Share	-$24.94K	-$0.04	-$0.04
COMMON SHARES
Basic Shares Outstanding	32.86M shares	31.08M shares	27.08M shares
Diluted Shares Outstanding		31.08M shares	27.08M shares

Balance Sheet

Concept	2017 Q4	2017 Q3	2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$9.900M	$9.400M	$9.300M
YoY Change	-31.72%	1.08%	-29.55%
Cash & Equivalents	$9.949M	$9.411M	$9.329M
Short-Term Investments
Other Short-Term Assets	$1.200M	$1.400M	$1.400M
YoY Change	0.0%	0.0%	-22.22%
Inventory	$4.274M	$7.335M	$5.900M
Prepaid Expenses
Receivables	$4.857M	$4.077M	$3.900M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$22.55M	$22.24M	$20.50M
YoY Change	-15.04%	8.47%	-13.5%
LONG-TERM ASSETS
Property, Plant & Equipment	$6.033M	$6.376M	$6.500M
YoY Change	-6.45%	-1.91%	-7.14%
Goodwill	$185.0K	$185.0K
YoY Change	0.0%
Intangibles	$1.510M	$1.510M
YoY Change	0.0%
Long-Term Investments
YoY Change
Other Assets	$67.00K	$119.0K	$200.0K
YoY Change	-34.95%	-40.5%	-66.67%
Total Long-Term Assets	$8.441M	$8.463M	$8.600M
YoY Change	-1.52%	-1.59%	-8.51%
TOTAL ASSETS
Total Short-Term Assets	$22.55M	$22.24M	$20.50M
Total Long-Term Assets	$8.441M	$8.463M	$8.600M
Total Assets	$30.99M	$30.70M	$29.10M
YoY Change	-11.74%	5.49%	-12.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.583M	$1.387M	$1.700M
YoY Change	-1.43%	-18.41%	-26.09%
Accrued Expenses	$861.0K	$2.657M	$2.300M
YoY Change	-66.94%	15.52%	9.52%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$239.0K	$239.0K	$200.0K
YoY Change	0.0%	19.5%	0.0%
Total Short-Term Liabilities	$5.973M	$4.806M	$4.200M
YoY Change	13.3%	14.43%	-10.64%
LONG-TERM LIABILITIES
Long-Term Debt	$2.455M	$2.515M	$2.900M
YoY Change	-8.87%	-13.28%	-3.33%
Other Long-Term Liabilities	$100.0K	$200.0K	$800.0K
YoY Change	-50.0%	-75.0%	166.67%
Total Long-Term Liabilities	$2.555M	$2.515M	$3.700M
YoY Change	-5.16%	-32.03%	12.12%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.973M	$4.806M	$4.200M
Total Long-Term Liabilities	$2.555M	$2.515M	$3.700M
Total Liabilities	$8.956M	$8.182M	$8.500M
YoY Change	0.78%	-3.74%	0.0%
SHAREHOLDERS EQUITY
Retained Earnings	-$28.50M	-$27.67M
YoY Change	21.6%
Common Stock	$33.00K	$33.00K
YoY Change	6.45%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$22.03M	$22.52M	$20.63M
YoY Change
Total Liabilities & Shareholders Equity	$30.99M	$30.70M	$29.10M
YoY Change	-11.74%	5.49%	-12.08%

Cashflow Statement

Concept	2017 Q4	2017 Q3	2016 Q3
OPERATING ACTIVITIES
Net Income	-$820.0K	-$2.944M	-$965.0K
YoY Change	57.69%	205.08%	-39.31%
Depreciation, Depletion And Amortization	$170.0K	$171.0K	$201.0K
YoY Change	0.0%	-14.93%	-4.29%
Cash From Operating Activities	$740.0K	-$550.0K	$90.00K
YoY Change	-234.55%	-711.11%	-113.85%
INVESTING ACTIVITIES
Capital Expenditures	-$190.0K	-$280.0K	-$140.0K
YoY Change	72.73%	100.0%	0.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00
YoY Change
Cash From Investing Activities	-$190.0K	-$280.0K	-$140.0K
YoY Change	72.73%	100.0%	0.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-60.00K	-60.00K	60.00K
YoY Change	-101.04%	-200.0%	-160.0%
NET CHANGE
Cash From Operating Activities	740.0K	-550.0K	90.00K
Cash From Investing Activities	-190.0K	-280.0K	-140.0K
Cash From Financing Activities	-60.00K	-60.00K	60.00K
Net Change In Cash	490.0K	-890.0K	10.00K
YoY Change	-90.41%	-9000.0%	-101.12%
FREE CASH FLOW
Cash From Operating Activities	$740.0K	-$550.0K	$90.00K
Capital Expenditures	-$190.0K	-$280.0K	-$140.0K
Free Cash Flow	$930.0K	-$270.0K	$230.0K
YoY Change	-311.36%	-217.39%	-145.1%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	bvx	Conversion Of Series B Convertible Preferred To Common Stock Amount ConversionOfSeriesBConvertiblePreferredToCommonStockAmount	0	USD
CY2016Q3	bvx	Dilutive Securities Effect On Basic Earnings Per Share Derivative Liability Warrant DilutiveSecuritiesEffectOnBasicEarningsPerShareDerivativeLiabilityWarrant	0	USD
	bvx	Dilutive Securities Effect On Basic Earnings Per Share Derivative Liability Warrant DilutiveSecuritiesEffectOnBasicEarningsPerShareDerivativeLiabilityWarrant	0	USD
CY2017Q3	bvx	Dilutive Securities Effect On Basic Earnings Per Share Derivative Liability Warrant DilutiveSecuritiesEffectOnBasicEarningsPerShareDerivativeLiabilityWarrant	0	USD
	bvx	Dilutive Securities Effect On Basic Earnings Per Share Derivative Liability Warrant DilutiveSecuritiesEffectOnBasicEarningsPerShareDerivativeLiabilityWarrant	0	USD
	bvx	Numberofproductlines Numberofproductlines	4	product_line
	bvx	Proceeds From Stock Options Exercised And Warrants Exercised ProceedsFromStockOptionsExercisedAndWarrantsExercised	119000	USD
	bvx	Proceeds From Stock Options Exercised And Warrants Exercised ProceedsFromStockOptionsExercisedAndWarrantsExercised	0	USD
	bvx	Stock Swap To Acquire Options Amount StockSwapToAcquireOptionsAmount	-315000	USD
	bvx	Stock Swap To Acquire Options Amount StockSwapToAcquireOptionsAmount	-275000	USD
	bvx	Warrant Exercised Amount WarrantExercisedAmount	316000	USD
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
	dei	Document Period End Date DocumentPeriodEndDate	2017-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0000719135
CY2017Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	32860785	shares
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	dei	Entity Registrant Name EntityRegistrantName	BOVIE MEDICAL CORP
	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1606000	USD
CY2017Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1387000	USD
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4733000	USD
CY2017Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4077000	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2604000	USD
CY2017Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2657000	USD
CY2016Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	419000	USD
CY2017Q3	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	193000	USD
CY2016Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	404000	USD
CY2017Q3	us-gaap	Accrued Vacation Current AccruedVacationCurrent	330000	USD
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	49625000	USD
CY2017Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	50156000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	533000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	532000	USD
CY2016Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	173000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	533000	USD
CY2017Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	191000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	532000	USD
CY2016Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	27000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	81000	USD
CY2017Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	27000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	81000	USD
CY2016Q4	us-gaap	Assets Assets	35110000	USD
CY2017Q3	us-gaap	Assets Assets	30699000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	26539000	USD
CY2017Q3	us-gaap	Assets Current AssetsCurrent	22236000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11805000	USD
CY2016Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9329000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14456000	USD
CY2017Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9411000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-2476000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-5045000	USD
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	40000000	shares
CY2017Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	31002832	shares
CY2017Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	32975174	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	30859753	shares
CY2017Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	32832095	shares
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	31000	USD
CY2017Q3	us-gaap	Common Stock Value CommonStockValue	33000	USD
CY2016Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	5002000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	14049000	USD
	us-gaap	Increase Decrease In Deposits IncreaseDecreaseInDeposits	9000	USD
	us-gaap	Increase Decrease In Derivative Assets IncreaseDecreaseInDerivativeAssets	-555000	USD
	us-gaap	Increase Decrease In Derivative Assets IncreaseDecreaseInDerivativeAssets	57000	USD
CY2017Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4753000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	13673000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	25000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2016Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	564000	USD
CY2017Q3	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	564000	USD
CY2016Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	14000	USD
CY2017Q3	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	11000	USD
CY2016Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	109000	USD
CY2017Q3	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	84000	USD
CY2016Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	201000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	556000	USD
CY2017Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	171000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	527000	USD
CY2016Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	203000	USD
CY2017Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	146000	USD
CY2016Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
CY2017Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.14
CY2016Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.04
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.13
CY2017Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.04
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.14
CY2016Q3	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2017Q3	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2016Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	215000	USD
CY2017Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	189000	USD
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-19000	USD
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-3000	USD
CY2016Q4	us-gaap	Goodwill Goodwill	185000	USD
CY2017Q3	us-gaap	Goodwill Goodwill	185000	USD
CY2016Q3	us-gaap	Gross Profit GrossProfit	5061000	USD
	us-gaap	Gross Profit GrossProfit	13084000	USD
CY2017Q3	us-gaap	Gross Profit GrossProfit	4594000	USD
	us-gaap	Gross Profit GrossProfit	13862000	USD
CY2016Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-965000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3428000	USD
CY2017Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1239000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4223000	USD
CY2016Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2017Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	6000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	15000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	436000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	337000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-528000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-250000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-337000	USD
	us-gaap	Increase Decrease In Deposits IncreaseDecreaseInDeposits	312000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-219000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1070000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1380000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	48000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	221000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-60000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	0	USD
CY2016Q3	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2017Q3	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2016Q4	us-gaap	Indefinite Lived Trademarks IndefiniteLivedTrademarks	1510000	USD
CY2017Q3	us-gaap	Indefinite Lived Trademarks IndefiniteLivedTrademarks	1510000	USD
CY2016Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-37000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-125000	USD
CY2017Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-36000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-103000	USD
	us-gaap	Interest Paid InterestPaid	125000	USD
	us-gaap	Interest Paid InterestPaid	103000	USD
CY2016Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	3048000	USD
CY2017Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	3804000	USD
CY2016Q4	us-gaap	Inventory Gross InventoryGross	7569000	USD
CY2017Q3	us-gaap	Inventory Gross InventoryGross	8949000	USD
CY2016Q4	us-gaap	Inventory Net InventoryNet	6158000	USD
CY2017Q3	us-gaap	Inventory Net InventoryNet	7335000	USD
CY2016Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	4521000	USD
CY2017Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	5145000	USD
CY2016Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	1411000	USD
CY2017Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	1614000	USD
	us-gaap	Inventory Write Down InventoryWriteDown	365000	USD
	us-gaap	Inventory Write Down InventoryWriteDown	203000	USD
CY2016Q3	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	57720	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	140000	USD
CY2017Q3	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	41385	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	126711	USD
CY2016Q4	us-gaap	Liabilities Liabilities	8887000	USD
CY2017Q3	us-gaap	Liabilities Liabilities	8182000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	35110000	USD
CY2017Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	30699000	USD
CY2017Q3	us-gaap	Liabilities Current LiabilitiesCurrent	4806000	USD
CY2017Q3	us-gaap	Long Term Debt LongTermDebt	2754000	USD
CY2016Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	239000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5272000	USD
CY2017Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	239000	USD
CY2017Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	60000	USD
CY2017Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	2455000	USD
CY2017Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	239000	USD
CY2016Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	2694000	USD
CY2017Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	2515000	USD
CY2016Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	140000	USD
CY2017Q3	us-gaap	Long Term Notes Payable LongTermNotesPayable	140000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-179000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-182000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-431000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2293000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4435000	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-965000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-3428000	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-1245000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-4238000	USD
CY2016Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-965000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3428000	USD
CY2017Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1245000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4238000	USD
CY2016Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-965000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-3428000	USD
CY2017Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-1245000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-4238000	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	3	segment
CY2016	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2016Q3	us-gaap	Operating Expenses OperatingExpenses	5306000	USD
	us-gaap	Operating Expenses OperatingExpenses	15832000	USD
CY2017Q3	us-gaap	Operating Expenses OperatingExpenses	5728000	USD
	us-gaap	Operating Expenses OperatingExpenses	18039000	USD
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-245000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2748000	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1134000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4177000	USD
CY2017Q3	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	514000	USD
CY2017Q3	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	47000	USD
CY2017Q3	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	73000	USD
CY2017Q3	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	73000	USD
CY2017Q3	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	132000	USD
CY2017Q3	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	189000	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	103000	USD
CY2017Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	119000	USD
CY2016Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-720000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-680000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	182000	USD
CY2017Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-105000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-46000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	431000	USD
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue	1000	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	413000	USD
CY2017Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	634000	USD
	us-gaap	Proceeds From Repayments Of Long Term Debt And Capital Securities ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities	-180000	USD
	us-gaap	Proceeds From Repayments Of Long Term Debt And Capital Securities ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities	-179000	USD
CY2016Q3	us-gaap	Professional Fees ProfessionalFees	292000	USD
	us-gaap	Professional Fees ProfessionalFees	1045000	USD
CY2017Q3	us-gaap	Professional Fees ProfessionalFees	421000	USD
	us-gaap	Professional Fees ProfessionalFees	1291000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6449000	USD
CY2017Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6376000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	126000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	128000	USD
CY2017Q3	us-gaap	Purchase Obligation PurchaseObligation	3600000	USD
CY2016Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	681000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1941000	USD
CY2017Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	610000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2015000	USD
CY2016Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	779000	USD
CY2017Q3	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	779000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-23434000	USD
CY2017Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-27672000	USD
CY2016Q3	us-gaap	Salaries And Wages SalariesAndWages	2192000	USD
	us-gaap	Salaries And Wages SalariesAndWages	6492000	USD
CY2017Q3	us-gaap	Salaries And Wages SalariesAndWages	2080000	USD
	us-gaap	Salaries And Wages SalariesAndWages	6783000	USD
CY2016Q3	us-gaap	Sales Revenue Net SalesRevenueNet	10063000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	27133000	USD
CY2017Q3	us-gaap	Sales Revenue Net SalesRevenueNet	9347000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	27535000	USD
CY2016Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2141000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6354000	USD
CY2017Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2617000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	7950000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	533000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	532000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.680
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.015
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	196803	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	4.99
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	628000	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3752209	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.64
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4078906	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.04
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.99
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.26
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	104500	shares
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	119000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	275000	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	23404000	USD
CY2016Q3	us-gaap	Stockholders Equity StockholdersEquity	20629000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	26223000	USD
CY2017Q3	us-gaap	Stockholders Equity StockholdersEquity	22517000	USD
CY2016Q3	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-683000	USD
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-555000	USD
CY2017Q3	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-69000	USD
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	57000	USD
CY2016Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	27075000	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	27059000	shares
CY2017Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	31078000	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	30932000	shares
CY2016Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	27075000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	27059000	shares
CY2017Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	31078000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	30932000	shares
CY2016Q3	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	27075000	shares
	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	27059000	shares
CY2017Q3	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	31078000	shares
	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	30932000	shares
CY2016Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	27075000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	27059000	shares
CY2017Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	31078000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	30932000	shares
	us-gaap	Description Of New Accounting Pronouncements Not Yet Adopted DescriptionOfNewAccountingPronouncementsNotYetAdopted	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">RECENT ACCOUNTING PRONOUNCEMENTS</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2017-04, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Intangibles-Goodwill and Other</font><font style="font-family:inherit;font-size:10pt;"> (Topic 350): </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Simplifying the Test for Goodwill Impairment</font><font style="font-family:inherit;font-size:10pt;">. The purpose of this ASU is to reduce the cost and complexity of evaluating goodwill for impairment. It eliminates the need for entities to calculate the implied fair value of goodwill by assigning the fair value of a reporting unit to all of its assets and liabilities as if that reporting unit had been acquired in a business combination. Under this ASU, an entity will perform its goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An impairment charge is recognized for the amount by which the carrying value exceeds the reporting unit's fair value. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. Early adoption is permitted, however we have chosen not to do so. The amendment is not expected to have a material impact on our financial condition or results of operations.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2016, the FASB issued ASU 2016-15, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Classification of Certain Cash Receipts and Cash Payments</font><font style="font-family:inherit;font-size:10pt;">. The new guidance clarifies the classification of certain cash receipts and cash payments in the statement of cash flows, including debt prepayment or extinguishment costs, settlement of contingent consideration arising from a business combination, insurance settlement proceeds, and distributions from certain equity method investees. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. Early adoption is permitted, however we have chosen not to do so. The amendment is not expected to have a material impact on our financial condition or results of operations.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, FASB issued ASU No. 2016-09</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> Compensation-Stock Compensation - (Topic 718)</font><font style="font-family:inherit;font-size:10pt;"> Improvements to employee share-based payments accounting as part of simplicity initiatives. This update involves several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. Some of the areas for simplification apply only to nonpublic entities. For us, the amendments in this Update are effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. The amendment has not made a material impact on our financial condition or results of operations.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, FASB issued ASU No. 2016-02, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842)</font><font style="font-family:inherit;font-size:10pt;">. The core principle of Topic 842 is that a lessee should recognize the assets and liabilities that arise from leases. ASU 2016-02 is effective for public companies for annual reporting periods beginning after December 15, 2018, and interim periods within those fiscal years. The guidance may be adopted prospectively or retrospectively and early adoption is permitted. The Company is currently assessing the impact the adoption of ASU 2016-02 will have on its consolidated financial statements.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued ASU No. 2014-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:inherit;font-size:10pt;">, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU No. 2014-09 will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard is effective for us on January 1, 2018. Early adoption is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. We performed an analysis and concluded that the amendment will not have a material impact on our financial condition or results of operations.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">No other new accounting pronouncement issued or effective during the fiscal year had or is expected to have a material impact on our consolidated financial statements or disclosures.</font></div></div>

Files In Submission

Name	View Source	Status
0000719135-17-000064-index-headers.html	Edgar Link	pending
0000719135-17-000064-index.html	Edgar Link	pending
0000719135-17-000064.txt	Edgar Link	pending
0000719135-17-000064-xbrl.zip	Edgar Link	pending
a2017q310-q.htm	Edgar Link	pending
a2017q310-qexhibit311.htm	Edgar Link	pending
a2017q310-qexhibit312.htm	Edgar Link	pending
a2017q310-qexhibit321.htm	Edgar Link	pending
a2017q310-qexhibit322.htm	Edgar Link	pending
a2017q3exhibit35.htm	Edgar Link	pending
bovielogo2017a02.jpg	Edgar Link	pending
bvx-20170930.xml	Edgar Link	completed
bvx-20170930.xsd	Edgar Link	pending
bvx-20170930_cal.xml	Edgar Link	unprocessable
bvx-20170930_def.xml	Edgar Link	unprocessable
bvx-20170930_lab.xml	Edgar Link	unprocessable
bvx-20170930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$APYX
Apyx Medical Corp Stock $apyx

2017 Q4 Form 10-Q Financial Statement

#000071913517000064 Filed on November 03, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$APYX Apyx Medical Corp Stock $apyx

2017 Q4 Form 10-Q Financial Statement

#000071913517000064 Filed on November 03, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$APYX
Apyx Medical Corp Stock $apyx